References
- Bassiri RM, Utiger RD. (1973). Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans. J Clin Invest 52:1616–19
- Cummins PM, O’Connor B. (1998). Pyroglutamyl peptidase: an overview of the three known enzymatic forms. Biochim Biophys Acta 1429:1–17
- Daimon CM, Chirdon P, Maudsley S, Martin B, (2013). The role of thyrotropin releasing hormone in aging and neurodegenerative diseases. Am J Alzheimers Dis 1. doi: 10.7726/ajad.2013.1003
- Griffiths EC. (1976). Peptidase inactivation of hypothalamic releasing hormones. Horm Res 7:179–91
- Guillemin R. (1978). Peptides in the brain: the new endocrinology of the neuron. Science 202:390–402
- Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33
- Ijiro T, Nakamura K, Ogata M, et al. (2015). Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system. Eur J Pharmacol 761:413–22
- Khomane KS, Meena CL, Jain R, Bansal AK. (2011). Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat 21:1673–91
- Kinoshita K, Yamamura M, Suzuki M, Matsuoka Y. (1998). Taltirelinhydrate (TA-0910): an orally active thyrotropin-releasing hormone mimetic agent with multiple actions. CNS Drug Rev 4:25–41
- Kodama H, Furuuchi S, Takahashi M, et al. (1997). Disposition of taltirelin (1): absorption, distribution, metabolism and excretion in rats and dogs. Yakubutsudoutai 12:460–74
- Matsunaga Y, Morimoto KH, Terauchi Y, et al. (1996). Disposition of posatirelin. (3). metabolites in rats. Yakubutsudoutai 11:273–9
- Morley JE. (1979). Extrahypothalamic thyrotropin releasing hormone (TRH) – its distribution and its functions. Life Sci 25:1539–50
- Ohno K, Pettigrew KD, Rapoport SI. (1978). Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235:H299–307
- O’Leary R, O’connor B. (1995). Thyrotropin-releasing hormone. J Neurochem 65:953–63
- Penner N, Xu L, Parakash C. (2012). Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513–31
- Schally AV. (1978). Aspects of hypothalamic regulation of the pituitary gland. Science 202:18–28
- Sobue I, Takayanagi T, Nakanishi T, et al. (1983). Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 61:235–48
- Sugimoto T, Hayashi T, Okita A, Morino A. (1996). Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 3rd communication: identification of metabolites in rat urine. Arzneimittelforschung 46:127–33
- Wolfer GK, Rippon WB. (1987). Protocols for use of ultrafiltration in determination of free ligand concentration and of complexity of ligand/protein interactions. Clin Chem 33:115–17
- Walker D, Brady J, Dalvie D, et al. (2009). A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22:1653–62
- Yamada M, Monden T, Konaka S, Mori M. (1993). Assignment of human thyrotropin-releasing hormone (TRH) receptor gene to chromosome 8. Somat Cell Mol Genet 19:577–80